Suryanarayan Somanathan

Suryanarayan Somanathan

Company: Pfizer

Job title: Head of AAV Gene Therapy, Rare Disease Research Unit


Overcoming Pre-existing Anti-AAV Neutralizing Antibodies 1:30 pm

Pre-existing anti-AAV neutralizing antibodies (NAbs) preclude some patients from receiving systemic AAV gene therapy Vector readministration is also currently impossible in patients who only realize suboptimal transgene expression due to high NAb from the first vector administration Emerging strategies that reduce or eliminate NAbs can increase patients treated with AAV while allowing vector readministrationRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.